FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130434229> ?p ?o ?g. }

• W2130434229 endingPage "88" @default.
• W2130434229 startingPage "82" @default.
• W2130434229 abstract "Abstract: The activity of fludarabine monophosphate (FLU) and α-interferon (α-IFN) in low-grade non-Hodgkin's lymphoma (LG-NHL) and B-cell chronic lymphocytic leukemia (B-CLL) has been demonstrated in several clinical trials. In a study of 137 previously treated patients, of whom 77 had B-CLL and 60 with LG-NHL, we used FLU as salvage chemotherapy. Dosages of 25 mg/m2 were given in 30-min infusions for 5 consecutive d. Treatment was repeated every 28 d depending on the patient's clinical status for a maximum of 6 cycles. Entrance to the α-IFN maintenance portion of the study depended on patient response to initial FLU. All patients who had obtained a complete or partial response after the FLU therapy were randomized to receive α-IFN or no further therapy. The α-IFN dose was 3×106 units 3 times per wk until disease progression. At 4 yr with a median follow-up of 22 months the percentage of patients with persistent response ranged between 20% and 30% among all the responders. Thirty-five (45%) B-CLL patients achieved major responses (complete/partial response), as did 29 (48%) of those with LG-NHL. Among the 64 patients who achieved a good response to initial therapy and who have entered the second part of the trial, there has been a rate of prolongation of remission in favour of maintenance α-IFN (p = 0.02). FLU therapy is an effective drug inducing remission in pretreated B-CLL and LH-NHL patients. However, as with other therapeutic modalities, remission is rarely maintained beyond 2 yr. So far, maintenance α-IFN has not been shown to produce significantly longer remission after treatment with FLU in LG-NHL, and there is no trend towards prolonged remission in B-CLL patients. The role of FLU needs to be further evaluated in the management of lymphoproliferative disorders by introducing it in combination with other drugs (α-IFN) in the induction phase and in maintenance treatment." @default.
• W2130434229 created "2016-06-24" @default.
• W2130434229 creator A5028241549 @default.
• W2130434229 creator A5029563827 @default.
• W2130434229 creator A5029836748 @default.
• W2130434229 creator A5033359713 @default.
• W2130434229 creator A5049395252 @default.
• W2130434229 creator A5055543156 @default.
• W2130434229 creator A5067436666 @default.
• W2130434229 creator A5071926851 @default.
• W2130434229 creator A5091882595 @default.
• W2130434229 date "2009-04-24" @default.
• W2130434229 modified "2023-10-16" @default.
• W2130434229 title "Results of a fludarabine induction and α-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma" @default.
• W2130434229 cites W154103547 @default.
• W2130434229 cites W15675347 @default.
• W2130434229 cites W1756818535 @default.
• W2130434229 cites W1779642901 @default.
• W2130434229 cites W1785340630 @default.
• W2130434229 cites W1848698181 @default.
• W2130434229 cites W190170648 @default.
• W2130434229 cites W1968102342 @default.
• W2130434229 cites W1990158591 @default.
• W2130434229 cites W1992964537 @default.
• W2130434229 cites W2027678183 @default.
• W2130434229 cites W2074490646 @default.
• W2130434229 cites W2076668534 @default.
• W2130434229 cites W2079668255 @default.
• W2130434229 cites W2093312029 @default.
• W2130434229 cites W2100195980 @default.
• W2130434229 cites W2129214379 @default.
• W2130434229 cites W2142799920 @default.
• W2130434229 cites W2278012184 @default.
• W2130434229 cites W2339387502 @default.
• W2130434229 cites W2439205875 @default.
• W2130434229 cites W4235582914 @default.
• W2130434229 cites W4246675764 @default.
• W2130434229 doi "https://doi.org/10.1111/j.1600-0609.1997.tb00730.x" @default.
• W2130434229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9293855" @default.
• W2130434229 hasPublicationYear "2009" @default.
• W2130434229 type Work @default.
• W2130434229 sameAs 2130434229 @default.
• W2130434229 citedByCount "15" @default.
• W2130434229 countsByYear W21304342292013 @default.
• W2130434229 countsByYear W21304342292014 @default.
• W2130434229 crossrefType "journal-article" @default.
• W2130434229 hasAuthorship W2130434229A5028241549 @default.
• W2130434229 hasAuthorship W2130434229A5029563827 @default.
• W2130434229 hasAuthorship W2130434229A5029836748 @default.
• W2130434229 hasAuthorship W2130434229A5033359713 @default.
• W2130434229 hasAuthorship W2130434229A5049395252 @default.
• W2130434229 hasAuthorship W2130434229A5055543156 @default.
• W2130434229 hasAuthorship W2130434229A5067436666 @default.
• W2130434229 hasAuthorship W2130434229A5071926851 @default.
• W2130434229 hasAuthorship W2130434229A5091882595 @default.
• W2130434229 hasConcept C126322002 @default.
• W2130434229 hasConcept C203014093 @default.
• W2130434229 hasConcept C2776694085 @default.
• W2130434229 hasConcept C2776755627 @default.
• W2130434229 hasConcept C2777866208 @default.
• W2130434229 hasConcept C2777938653 @default.
• W2130434229 hasConcept C2778283404 @default.
• W2130434229 hasConcept C2778461978 @default.
• W2130434229 hasConcept C2779263901 @default.
• W2130434229 hasConcept C2779338263 @default.
• W2130434229 hasConcept C71924100 @default.
• W2130434229 hasConcept C90924648 @default.
• W2130434229 hasConceptScore W2130434229C126322002 @default.
• W2130434229 hasConceptScore W2130434229C203014093 @default.
• W2130434229 hasConceptScore W2130434229C2776694085 @default.
• W2130434229 hasConceptScore W2130434229C2776755627 @default.
• W2130434229 hasConceptScore W2130434229C2777866208 @default.
• W2130434229 hasConceptScore W2130434229C2777938653 @default.
• W2130434229 hasConceptScore W2130434229C2778283404 @default.
• W2130434229 hasConceptScore W2130434229C2778461978 @default.
• W2130434229 hasConceptScore W2130434229C2779263901 @default.
• W2130434229 hasConceptScore W2130434229C2779338263 @default.
• W2130434229 hasConceptScore W2130434229C71924100 @default.
• W2130434229 hasConceptScore W2130434229C90924648 @default.
• W2130434229 hasIssue "2" @default.
• W2130434229 hasLocation W21304342291 @default.
• W2130434229 hasLocation W21304342292 @default.
• W2130434229 hasOpenAccess W2130434229 @default.
• W2130434229 hasPrimaryLocation W21304342291 @default.
• W2130434229 hasRelatedWork W2084629253 @default.
• W2130434229 hasRelatedWork W2097778142 @default.
• W2130434229 hasRelatedWork W2162794727 @default.
• W2130434229 hasRelatedWork W2256304711 @default.
• W2130434229 hasRelatedWork W2489650752 @default.
• W2130434229 hasRelatedWork W2503439872 @default.
• W2130434229 hasRelatedWork W2883739273 @default.
• W2130434229 hasRelatedWork W2980214149 @default.
• W2130434229 hasRelatedWork W3107545861 @default.
• W2130434229 hasRelatedWork W2184654608 @default.
• W2130434229 hasVolume "59" @default.
• W2130434229 isParatext "false" @default.
• W2130434229 isRetracted "false" @default.
• W2130434229 magId "2130434229" @default.

• next